Emergent BioSolutions Awarded $250+ Million in Contract to Supply U.S. Government with Four Critical Medical Countermeasure Products
| | | | | | |

Emergent BioSolutions Awarded $250+ Million in Contract to Supply U.S. Government with Four Critical Medical Countermeasure Products

On Jul. 2, 2024, Emergent BioSolutions announced it had received more than $250 millionin contract modifications from the…

USDA Approved Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
| | | | | |

USDA Approved Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza

On Jun. 25, 2024, Merck Animal Health announced U.S. Department of Agriculture (USDA) approval of NOBIVAC® NXT Canine…

U.S. FDA Approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
| | | | |

U.S. FDA Approved CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

On Jun. 17, 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVE™ (Pneumococcal…